J9199 – Injection, gemcitabine hydrochloride (infugem), 200 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9199
- Long description
- Injection, gemcitabine hydrochloride (infugem), 200 mg
- Short description
- Injection, infugem, 200 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- Added
- January 1, 2020
- Last change
- July 1, 2020 – No change
- Termination date
- June 30, 2020
Frequently asked questions
What is HCPCS code J9199?
J9199 is a HCPCS Level II code for injection, gemcitabine hydrochloride (infugem), 200 mg. It was discontinued on June 30, 2020.
Does Medicare cover J9199?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9185 – Injection, fludarabine phosphate, 50 mg
- J9186 – Injection, etoposide (avyxa), 1 mg
- J9187 – Injection, etoposide, 1 mg
- J9190 – Injection, fluorouracil, 500 mg
- J9191 – Injection, fluorouracil (avyxa), 10 mg
- J9192 – Injection, fluorouracil, 10 mg
- J9196 – Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
- J9198 – Injection, gemcitabine hydrochloride, (infugem), 100 mg
- J9200 – Injection, floxuridine, 500 mg
- J9201 – Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202 – Goserelin acetate implant, per 3.6 mg
- J9203 – Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204 – Injection, mogamulizumab-kpkc, 1 mg
- J9205 – Injection, irinotecan liposome, 1 mg
- J9206 – Injection, irinotecan, 20 mg
- J9207 – Injection, ixabepilone, 1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.